The DOI matches its Crossref record.
MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil
Open accessAbstract
MK-1775 is a potent and selective small molecule Wee1 inhibitor. Previously we have shown that it abrogated DNA damaged checkpoints induced by gemcitabine, carboplatin, and cisplatin and enhanced the anti-tumor efficacy of these agents selectively in p53-deficient tumor cells. MK-1775 is currently in Phase I clinical trial in combination with these anti-cancer drugs. In this study, the effects of MK-1775 on 5-fluorouracil (5-FU) and other DNA-damaging agents with different modes of action were determined. MK-1775 enhanced the cytotoxic effects of 5-FU in p53-deficient human colon cancer cells. MK-1775 inhibited CDC2 Y15 phosphorylation in cells, abrogated DNA damaged checkpoints induced by 5-FU treatment, and caused premature entry of mitosis determined by induction of Histone H3 phosphorylation. Enhancement by MK-1775 was specific for p53-deficient cells since this compound did not sensitize p53-wild type human colon cancer cells to 5-FU in vitro. In vivo, MK-1775 potentiated the anti-tumor efficacy of 5-FU or its prodrug, capecitabine, at tolerable doses. These enhancements were well correlated with inhibition of CDC2 phosphorylation and induction of Histone H3 phosphorylation in tumors. In addition, MK-1775 also potentiated the cytotoxic effects of pemetrexed, doxorubicin, camptothecin, and mitomycin C in vitro. These studies support the rationale for testing the combination of MK-1775 with various DNA-damaging agents in cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 527
Unravelling the biology of SCLC: implications for therapy
Sabari, J. K., Lok, B. H., Laird, J. H., Poirier, J. T., & Rudin, C. M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.71 · Cited by 490
Targeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408
Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword
Visconti, R., Della Monica, R., & Grieco, D. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0433-9 · Cited by 366
Targeting replication stress in cancer therapy
da Costa, A. A. B. A., Chowdhury, D., Shapiro, G. I., D’Andrea, A. D., & Konstantinopoulos, P. A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00558-5 · Cited by 359
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
Aarts, M., Sharpe, R., Garcia-Murillas, I., Gevensleben, H., Hurd, M. S., Shumway, S. D., Toniatti, C., Ashworth, A., & Turner, N. C. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0320 · Cited by 327
DNA damage checkpoint kinases in cancer
Smith, H. L., Southgate, H., Tweddle, D. A., & Curtin, N. J. (2020) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2020.3 · Cited by 322
Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Sorensen, C. S., & Syljuasen, R. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr697 · Cited by 318
A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target
Ghelli Luserna di Rorà, A., Cerchione, C., Martinelli, G., & Simonetti, G. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00959-2 · Cited by 314
Rajeshkumar, N. V., De Oliveira, E., Ottenhof, N., Watters, J., Brooks, D., Demuth, T., Shumway, S. D., Mizuarai, S., Hirai, H., Maitra, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2580 · Cited by 274
Self-citationWee1 kinase as a target for cancer therapy
Do, K., Doroshow, J. H., & Kummar, S. (2013) · Cell Cycle · doi:10.4161/cc.26062 · Cited by 273
Leijen, S., van Geel, R. M. J. M., Pavlick, A. C., Tibes, R., Rosen, L., Razak, A. R. A., Lam, R., Demuth, T., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5991 · Cited by 264
Oza, A. M., Estevez-Diz, M., Grischke, E.-M., Hall, M., Marmé, F., Provencher, D., Uyar, D., Weberpals, J. I., Wenham, R. M., Laing, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0219 · Cited by 129
“Median age, years (range) 58 (42–77) 60 (40–80) Race, n (%) White 53 (90) 52 (84) Asian 5 (9) 8 (13) American Indian/Alaskan native 1 (2) 1 (2) Black/African American 0 1 (2) ECOG performance status, n (%) 0 38 (64) 35 (57) 1 21 (36) 27 (44) Primary tumor location, n (%) Ovary 55 (93) 53 (85) Fallopian tube or primary…”
Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials
Nishikawa, S., & Iwakuma, T. (2023) · Cancers · doi:10.3390/cancers15020429 · Cited by 115
Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity
Wright, G., Golubeva, V., Remsing Rix, L. L., Berndt, N., Luo, Y., Ward, G. A., Gray, J. E., Schonbrunn, E., Lawrence, H. R., Monteiro, A. N. A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00147 · Cited by 77
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022) · Cancers · doi:10.3390/cancers14194874 · Cited by 62
Chen, B., Duan, L., Yin, G., Tan, J., & Jiang, X. (2013) · Journal of Chemotherapy · doi:10.1179/1973947813y.0000000092 · Cited by 51
Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A., & Niegisch, G. (2021) · Genes · doi:10.3390/genes12020260 · Cited by 28
“MK‐1775 (AZD1775) is a specific inhibitor of WEE1 that is already evaluated in clinical trials [47].”
BackgroundAriyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024) · Cancers · doi:10.3390/cancers16183136 · Cited by 12
“The association between the effects of WEE1 inhibitors and p53 or KRAS mutation status has been investigated in various cancers; however, some studies have highlighted the correlation between p53 or KRAS mutation status and the effects of WEE1 inhibitors [7], whereas others have not [13].”
BackgroundWEE1 confers resistance to KRASG12C inhibitors in non-small cell lung cancer
Yamamoto, G., Tanaka, K., Kamata, R., Saito, H., Yamamori-Morita, T., Nakao, T., Liu, J., Mori, S., Yagishita, S., Hamada, A., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2024.217414 · Cited by 11
Metadata
- Authors
- Hirai, H., Arai, T., Okada, M., Nishibata, T., Kobayashi, M., Sakai, N., Imagaki, K., Ohtani, J., Sakai, T., Yoshizumi, T., Mizuarai, S., Iwasawa, Y., & Kotani, H.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-04
- Volume
- 9
- Issue
- 7
- Pages
- 514-522
- ISSN
- 1538-4047 (ISSN-L)
- 1555-8576
- OpenAlex
- W2028495676
- Cited by
- 237
- References
- 0
- FWCI
- 5.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.